Carla López-Causapé
Carla López-Causapé
Hospital Son Espases
Verified email at - Homepage
Cited by
Cited by
The increasing threat of Pseudomonas aeruginosa high-risk clones
A Oliver, X Mulet, C López-Causapé, C Juan
Drug Resistance Updates 21, 41-59, 2015
The Versatile Mutational Resistome of Pseudomonas aeruginosa
C López-Causapé, G Cabot, E del Barrio-Tofiño, A Oliver
Frontiers in microbiology 9, 685, 2018
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update
E del Barrio-Tofiño, C López-Causapé, A Oliver
International journal of antimicrobial agents 56 (6), 106196, 2020
Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain
E del Barrio-Tofiño, C López-Causapé, G Cabot, A Rivera, N Benito, ...
Antimicrobial agents and chemotherapy 61 (11), 10.1128/aac. 01589-17, 2017
Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone
C López-Causapé, LM Sommer, G Cabot, R Rubio, AA Ocampo-Sosa, ...
Scientific reports 7 (1), 5555, 2017
Deciphering the resistome of the widespread Pseudomonas aeruginosa sequence type 175 international high-risk clone through whole-genome sequencing
G Cabot, C López-Causapé, AA Ocampo-Sosa, LM Sommer, ...
Antimicrobial agents and chemotherapy 60 (12), 7415-7423, 2016
Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology
E del Barrio-Tofiño, L Zamorano, S Cortes-Lara, C López-Causapé, ...
Journal of Antimicrobial Chemotherapy 74 (7), 1825-1835, 2019
Clonal Dissemination, Emergence of Mutator Lineages and Antibiotic Resistance Evolution in Pseudomonas aeruginosa Cystic Fibrosis Chronic Lung Infection
C Lopez-Causape, E Rojo-Molinero, X Mulet, G Cabot, B Moya, ...
PLoS One 8 (8), e71001, 2013
The problems of antibiotic resistance in cystic fibrosis and solutions
C López-Causapé, E Rojo-Molinero, MD Macia, A Oliver
Expert review of respiratory medicine 9 (1), 73-88, 2015
Evolution of the Pseudomonas aeruginosa Aminoglycoside Mutational Resistome In Vitro and in the Cystic Fibrosis Setting
C López-Causapé, R Rubio, G Cabot, A Oliver
Antimicrobial agents and chemotherapy 62 (4), 10.1128/aac. 02583-17, 2018
Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic β-lactam-resistant mutants
PA Fraile-Ribot, L Zamorano, R Orellana, E del Barrio-Tofiño, ...
Antimicrobial Agents and Chemotherapy 64 (2), 10.1128/aac. 02165-19, 2020
The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant
MG López, Á Chiner-Oms, D García de Viedma, P Ruiz-Rodriguez, ...
Nature genetics 53 (10), 1405-1414, 2021
Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands
M Díaz-Cañestro, L Periañez, X Mulet, ML Martin-Pena, PA Fraile-Ribot, ...
European Journal of Clinical Microbiology & Infectious Diseases 37, 2191-2200, 2018
Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute Pseudomonas aeruginosa infection
R Wheatley, J Diaz Caballero, N Kapel, FHR De Winter, P Jangir, A Quinn, ...
Nature Communications 12 (1), 2460, 2021
Characterization of hypermutator Pseudomonas aeruginosa isolates from patients with cystic fibrosis in Australia
VE Rees, DS Deveson Lucas, C López-Causapé, Y Huang, T Kotsimbos, ...
Antimicrobial agents and chemotherapy 63 (4), 10.1128/aac. 02538-18, 2019
Interplay among resistance profiles, high-risk clones, and virulence in the Caenorhabditis elegans Pseudomonas aeruginosa infection model
I Sánchez-Diener, L Zamorano, C López-Causapé, G Cabot, X Mulet, ...
Antimicrobial Agents and Chemotherapy 61 (12), 10.1128/aac. 01586-17, 2017
Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis
S Cortes-Lara, E del Barrio-Tofiño, C López-Causapé, A Oliver, ...
Clinical Microbiology and Infection 27 (11), 1631-1637, 2021
Sequential treatment of biofilms with aztreonam and tobramycin is a novel strategy for combating Pseudomonas aeruginosa chronic respiratory infections
E Rojo-Molinero, MD Macià, R Rubio, B Moyà, G Cabot, ...
Antimicrobial Agents and Chemotherapy 60 (5), 2912-2922, 2016
Emergence of resistance to novel cephalosporin–β-Lactamase inhibitor combinations through the modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump
MA Gomis-Font, C Pitart, E del Barrio-Tofiño, Y Zboromyrska, ...
Antimicrobial Agents and Chemotherapy 65 (8), 10.1128/aac. 00089-21, 2021
Susceptibility profiles and resistance genomics of Pseudomonas aeruginosa isolates from European ICUs participating in the ASPIRE-ICU trial
G Torrens, TE van der Schalk, S Cortes-Lara, L Timbermont, ...
Journal of Antimicrobial Chemotherapy 77 (7), 1862-1872, 2022
The system can't perform the operation now. Try again later.
Articles 1–20